SLC5A2 and type 1 diabetes mellitus: In September 2023, revisions to the “warning and precaution sections” of the product labels for SGLT2 inhibitors highlighted the risk of DKA, particularly in patients with T1DM or those predisposed to ketoacidosis [13].